Genmab AS Asset Resilience Ratio

Latest as of December 2025: 0.00%

Genmab AS asset resilience ratio. Genmab AS (GMAB) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Genmab AS fund operations to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$0.00

Cash + Short-term Investments

Total Assets

$12.84 Billion

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of Genmab AS (2005–2025)

Asset resilience ratio of Genmab AS from 2005 to 2025. This chart shows how Genmab AS's Asset Resilience Ratio has changed over time. Read GMAB total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Genmab AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Genmab AS balance sheet assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$0.00	0%
Total Liquid Assets	$0.00	0.00%

Asset Resilience Insights

Limited Liquidity: Genmab AS maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

Genmab AS Industry Peers by Asset Resilience Ratio

Compare Genmab AS's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
HLB Co. Ltd KQ:028300	Biotechnology	3.29%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Shanghai Medicilon Inc SHG:688202	Biotechnology	6.69%
Blue Jet Healthcare Limited NSE:BLUEJET	Biotechnology	13.81%
Hangzhou Biotest Biotech Co Ltd SHG:688767	Biotechnology	0.56%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	79.76%
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	Biotechnology	5.52%

Genmab AS Asset Resilience Ratio by Year (2005–2025)

Genmab AS asset resilience ratio by year from 2005 to 2025. The table below shows the annual Asset Resilience Ratio data for Genmab AS.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.00%	$0.00	$12.84 Billion	--
2024-12-31	24.54%	$11.24 Billion	$45.81 Billion	-13.06pp
2023-12-31	37.60%	$13.27 Billion	$35.29 Billion	-3.67pp
2022-12-31	41.27%	$12.43 Billion	$30.12 Billion	-0.88pp
2021-12-31	42.15%	$10.38 Billion	$24.63 Billion	+0.44pp
2020-12-31	41.71%	$8.82 Billion	$21.14 Billion	-7.28pp
2019-12-31	48.99%	$7.42 Billion	$15.14 Billion	-16.88pp
2018-12-31	65.87%	$5.57 Billion	$8.46 Billion	+4.15pp
2017-12-31	61.72%	$4.08 Billion	$6.60 Billion	-7.29pp
2016-12-31	69.01%	$3.61 Billion	$5.24 Billion	+1.89pp
2015-12-31	67.12%	$2.62 Billion	$3.90 Billion	-13.17pp
2014-12-31	80.28%	$2.30 Billion	$2.87 Billion	+0.07pp
2013-12-31	80.21%	$1.39 Billion	$1.73 Billion	-4.66pp
2012-12-31	84.87%	$1.44 Billion	$1.69 Billion	+18.69pp
2011-12-31	66.19%	$1.04 Billion	$1.56 Billion	+3.79pp
2010-12-31	62.39%	$1.55 Billion	$2.48 Billion	+25.62pp
2009-12-31	36.77%	$816.91 Million	$2.22 Billion	-53.20pp
2007-12-31	89.97%	$3.56 Billion	$3.96 Billion	+18.20pp
2006-12-31	71.77%	$1.30 Billion	$1.80 Billion	+8.18pp
2005-12-31	63.60%	$871.56 Million	$1.37 Billion	--

pp = percentage points

About Genmab AS

NASDAQ:GMAB USA Biotechnology

Market Cap

$35.03 Billion

Market Cap Rank

#1494 Global

#594 in USA

Share Price

$57.06

Change (1 day)

+1.01%

52-Week Range

$23.85 - $57.29

All Time High

$57.29